Osteoporosis: Difference between revisions

From Opasnet
Jump to navigation Jump to search
 
(7 intermediate revisions by the same user not shown)
Line 1: Line 1:
[[Category:Health effects]]
[[Category:Health effects]]
{{variable|moderator=Teemu R}}
{{template:Heimtsa incidence database|moderator=Teemu R}}
==Scope==
==Scope==
What is the prevalence of osteoporosis in the general population?
What is the prevalence of osteoporosis in the general population?
Line 6: Line 6:
==Definition==
==Definition==
{| {{prettytable}}
{| {{prettytable}}
! Rate (age, sex ratio)
! Context (population size studied, location, date data taken, end-point measured)
! Definition of end-point
! Reference
|----
| Spain: ~2 million women with osteoporosis; prevalent in 26.1% of women 50+
| Spain: ~2 million women with osteoporosis; prevalent in 26.1% of women 50+
| Contains information on fractures and prevalence of osteoporosis across Europe with references for each of the facts
| Contains information on fractures and prevalence of osteoporosis across Europe with references for each of the facts
|  
|  
| International Osteoporosis Foundation <br/>http://www.iofbonehealth.org/facts-and-statistics.html
| <ref>International Osteoporosis Foundation http://www.iofbonehealth.org/facts-and-statistics.html</ref>
|----
|----
| 7.8 million affected (6.5 million women)
| 7.8 million affected (6.5 million women)
| Germany, 2003
| Germany, 2003
| Claims data for patients with osteoporosis (M80, M81) or an osteoporosis-related fracture diagnosis (S22, S32, S42, S52, S72, S82) or treatment with anti-osteoporosis drugs  
| Claims data for patients with osteoporosis (M80, M81) or an osteoporosis-related fracture diagnosis (S22, S32, S42, S52, S72, S82) or treatment with anti-osteoporosis drugs  
| Epidemiology, treatment and costs of osteoporosis in Germany – the BoneEVA Study; Osteoporosis Int. 2007 v.18(1):77-84
| <ref>Epidemiology, treatment and costs of osteoporosis in Germany – the BoneEVA Study; Osteoporosis Int. 2007 v.18(1):77-84</ref>
|----
|----
| 40.8% in women &gt;50 and 17.7% in men &gt;50
| 40.8% in women &gt;50 and 17.7% in men &gt;50
| Denmark, 1995-1999
| Denmark, 1995-1999
| Based on normal Danish values for BMD, the expected number of subjects aged 50 years + with osteoporosis according to the WHO definition was calculated
| Based on normal Danish values for BMD, the expected number of subjects aged 50 years + with osteoporosis according to the WHO definition was calculated
| Osteoporosis is markedly underdiagnosed: a nationwide study from Denmark; Osteoporos Int. 2005 Feb;16(2):134-41.
| <ref>Osteoporosis is markedly underdiagnosed: a nationwide study from Denmark; Osteoporos Int. 2005 Feb;16(2):134-41.</ref>
|----
|----
| Women, 45-59yrs <br/>5.0% had a BMD &lt;2.5 SD of the mean premenopausal reference value and were thus considered to be osteoporotic. <br/>Patients were classified as slow (41.7%), borderline (28.2%), and fast (30.1%) bone losers. <br/>By integrating the estimated annual percent bone loss with baseline bone mineral content, 27.6% of the postmenopausal women were identified as at risk of developing osteoporosis at age 65 years.
| Women, 45-59yrs <br/>5.0% had a BMD &lt;2.5 SD of the mean premenopausal reference value and were thus considered to be osteoporotic. <br/>Patients were classified as slow (41.7%), borderline (28.2%), and fast (30.1%) bone losers. <br/>By integrating the estimated annual percent bone loss with baseline bone mineral content, 27.6% of the postmenopausal women were identified as at risk of developing osteoporosis at age 65 years.
| n=2286, Italy, risk of osteoporosis
| n=2286, Italy, risk of osteoporosis
| Risk of osteoporosis by combining a baseline distal forearm bone mineral content measurement with an estimation of annual percent bone loss as shown by plasma bone Gla protein, serum alkaline phosphatase, and fasting urinary creatinine-corrected calcium and hydroxyproline
| Risk of osteoporosis by combining a baseline distal forearm bone mineral content measurement with an estimation of annual percent bone loss as shown by plasma bone Gla protein, serum alkaline phosphatase, and fasting urinary creatinine-corrected calcium and hydroxyproline
| AGNUSDEI D. CALCAGNO V. CHRISTIANSEN C. CREPALDI G. GENNARI C. MARTINI L.  MAZZUOLI G. F. PASQUARELLI V.  Prevalence of osteoporosis and prediction of osteoporosis risk in Italian peri- and postmenopausal women : The detection of osteoporosis risk (door) study. <br/>Current therapeutic research 1996, vol. 57, no2, pp. 110-122.
| <ref>AGNUSDEI D. CALCAGNO V. CHRISTIANSEN C. CREPALDI G. GENNARI C. MARTINI L.  MAZZUOLI G. F. PASQUARELLI V.  Prevalence of osteoporosis and prediction of osteoporosis risk in Italian peri- and postmenopausal women : The detection of osteoporosis risk (door) study. Current therapeutic research 1996, vol. 57, no2, pp. 110-122. </ref>
|-
|----
|
{| {{prettytable}}
{| {{prettytable}}
| Prevalence of osteoporosis at the age intervals shown in Sweden using female-derived reference ranges at the femoral neck. (Reprinted from [24)  
| colspan="5"| Prevalence of osteoporosis at the age intervals shown in Sweden using female-derived reference ranges at the femoral neck. (Reprinted from [24] ''reference missing'')  
|----
|----
| Men  
|
|  
| colspan="2"| Men  
| Women  
| colspan="2"| Women  
|
|----
|----
| Age range  
| Age range  
Line 97: Line 102:
| Sweden, osteoporosis, paper contains other tables and data
| Sweden, osteoporosis, paper contains other tables and data
| WHO criteria
| WHO criteria
| J. A. Kanis, N. Burlet, C. Cooper, P. D. Delmas, J.-Y. Reginster, F. Borgstrom, R. Rizzoli and on behalf of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Journal Osteoporosis International, Volume 19, Number 4 / April, 2008
| <ref>J. A. Kanis, N. Burlet, C. Cooper, P. D. Delmas, J.-Y. Reginster, F. Borgstrom, R. Rizzoli and on behalf of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Journal Osteoporosis International, Volume 19, Number 4 / April, 2008</ref>
|----
|----
|}
|}

Latest revision as of 11:15, 1 July 2010


Scope

What is the prevalence of osteoporosis in the general population?

Definition

Rate (age, sex ratio) Context (population size studied, location, date data taken, end-point measured) Definition of end-point Reference
Spain: ~2 million women with osteoporosis; prevalent in 26.1% of women 50+ Contains information on fractures and prevalence of osteoporosis across Europe with references for each of the facts [1]
7.8 million affected (6.5 million women) Germany, 2003 Claims data for patients with osteoporosis (M80, M81) or an osteoporosis-related fracture diagnosis (S22, S32, S42, S52, S72, S82) or treatment with anti-osteoporosis drugs [2]
40.8% in women >50 and 17.7% in men >50 Denmark, 1995-1999 Based on normal Danish values for BMD, the expected number of subjects aged 50 years + with osteoporosis according to the WHO definition was calculated [3]
Women, 45-59yrs
5.0% had a BMD <2.5 SD of the mean premenopausal reference value and were thus considered to be osteoporotic.
Patients were classified as slow (41.7%), borderline (28.2%), and fast (30.1%) bone losers.
By integrating the estimated annual percent bone loss with baseline bone mineral content, 27.6% of the postmenopausal women were identified as at risk of developing osteoporosis at age 65 years. 		n=2286, Italy, risk of osteoporosis Risk of osteoporosis by combining a baseline distal forearm bone mineral content measurement with an estimation of annual percent bone loss as shown by plasma bone Gla protein, serum alkaline phosphatase, and fasting urinary creatinine-corrected calcium and hydroxyproline [4]
Prevalence of osteoporosis at the age intervals shown in Sweden using female-derived reference ranges at the femoral neck. (Reprinted from [24] reference missing)
Men Women
Age range %of Number %of Number
(years) population affected (000) population affected (000)
50–54 2.5 7.0 6.3 17.0
55–59 3.5 7.6 9.6 21.1
60–64 5.8 11.4 14.3 30.0
65–69 7.4 14.2 20.2 43.7
70–74 7.8 14.6 27.9 63.0
75–79 10.3 13.7 37.5 68.3
80–84 16.6 14.7 47.2 67.8
50–80 6.3 83.2 21.2 310.9
Sweden, osteoporosis, paper contains other tables and data WHO criteria [5]

Result

{{#opasnet_base_link:Op_en4523}}


See also

Related files

<mfanonymousfilelist></mfanonymousfilelist>


References

  1. ↑ International Osteoporosis Foundation http://www.iofbonehealth.org/facts-and-statistics.html
  2. ↑ Epidemiology, treatment and costs of osteoporosis in Germany – the BoneEVA Study; Osteoporosis Int. 2007 v.18(1):77-84
  3. ↑ Osteoporosis is markedly underdiagnosed: a nationwide study from Denmark; Osteoporos Int. 2005 Feb;16(2):134-41.
  4. ↑ AGNUSDEI D. CALCAGNO V. CHRISTIANSEN C. CREPALDI G. GENNARI C. MARTINI L. MAZZUOLI G. F. PASQUARELLI V. Prevalence of osteoporosis and prediction of osteoporosis risk in Italian peri- and postmenopausal women : The detection of osteoporosis risk (door) study. Current therapeutic research 1996, vol. 57, no2, pp. 110-122.
  5. ↑ J. A. Kanis, N. Burlet, C. Cooper, P. D. Delmas, J.-Y. Reginster, F. Borgstrom, R. Rizzoli and on behalf of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Journal Osteoporosis International, Volume 19, Number 4 / April, 2008
Retrieved from "https://en.opasnet.org/index.php?title=Osteoporosis&oldid=16458"